U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 35 results

Status:
US Approved Rx (2014)
First approved in 2014

Class (Stereo):
CHEMICAL (ACHIRAL)



Belinostat is a hydroxamate-type histone deacetylase inhibitor indicated for the treatment of relapsed or refractory peripheal T-cell lymphoma. The compound received orphan drug designation for the treatment of malignant thymomas. Acting on a histone...
Status:
US Approved Rx (2006)
First approved in 2006

Class (Stereo):
CHEMICAL (ACHIRAL)



Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Cla...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Dacinostat (also known as LAQ824), is a hydroxamate histone deacetylase inhibitor with potential anticancer activity. Dacinostat inhibits histone deacetylase enzymatic activities in vitro and transcriptionally activated the p21 promoter in reporter g...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Mocetinostat is an rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 a...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Gavinostat is an orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. Gavinostat inhibits class I and class II HDACs, resulting in an accumulation of...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



4SC-202 is an epigenetic oncology compound with a unique therapeutic profile, which was developed by biotechnology company: 4SC. 4SC-202 works as a selective inhibitor of LSD1 (lysine-specific demethylase 1) and HDAC (histone deacetylase) 1, 2 and 3....
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



CUDC-907 is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other ma...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


HDAC-IN-2 (also known as citarinostat or ACY-241) was developed as a selective histone deacetylase (HDAC) 6 inhibitor with potential antineoplastic activity. Inhibition of HDAC leads to the inhibition of tumor oncogene transcription, and the selectiv...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Abexinostat (PCI-24781) is a novel, second-generation phenyl hydroxamic acid–based, orally bioavailable HDAC inhibitor that has previously been shown to have activity in vitro and in vivo against a broad array of cancers, including hematopoietic mali...